A Phase 1/2 interventional study of AZD0305 and Elranatamab in Multiple Myeloma, sponsored by AstraZeneca. Recruiting at 46 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Multiple Myeloma by AstraZeneca — 8 open to participants now, 8 under way, 3 of them phase 3. Multiple Myeloma · AstraZeneca.
Among the 16 studies in Multiple Myeloma by AstraZeneca, this one is the 5th largest by planned enrollment, is one of 3 that started in 2023, is one of 7 in phase 1/2, and was the 10th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →8 of the 16 studies in Multiple Myeloma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Australia, Brazil and 15 more countries
Ages 18–130
AstraZeneca · Sites in United States, Australia
Ages 18+
AstraZeneca · Sites in United States, Australia, Brazil and 12 more countries
Ages 18+
AstraZeneca · Sites in United States, Australia, Brazil and 12 more countries
Ages 18+
AstraZeneca · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 586 Multiple Myeloma studies recruiting now, 431 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 7 · Phase 3 3
First in 2008; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 226 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 104 across the 16 interventional studies. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
1 of the studies in Multiple Myeloma by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05850234AstraZenecaAZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1) | 2027-10-01 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Multiple Myeloma by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics and efficacy of AZD0305 as monotherapy and in combination with other anticancer agents in participants with MM.
This study will follow a modular protocol design evaluating AZD0305 as monotherapy and in combination with other anticancer agents. The protocol may be amended in the future to incorporate further monotherapy expansion at the recommended Phase 2 dose (RP2D) in Phase II, and/or additional modules investigating AZD0305 in combination with other anticancer agents.
The study consists of 3 modules:
The criteria were revised on the registry on Oct 30, 2026. See what changed
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Module 1: Phase Ia: Dose Escalation Phase Ib: Dose Expansion/Optimization AZD0305 will be administered at specified dose levels.
Drug: AZD0305
Module2: Phase 1a: Dose escalation and Phase 1b: Backfills, AZD0305 will be administered in combination with elranatamab, following the module-specific dosing.
Drug: AZD0305 · Drug: Elranatamab
Module3: Phase 1a: Dose escalation and Phase 1b: Backfills, AZD0305 will be administered in combination with pomalidomide and dexamethasone, following the module-specific dosing.
Drug: AZD0305 · Drug: Pomalidomide · Drug: Dexamethasone
AZD0305 Investigational product
Module 2 Investigational product
Module 3 Standard of Care (background treatment)
Module 3 Standard of Care (background treatment)
Occurrence of dose-limiting toxicity (DLT), as defined in the protocol (Phase Ia dose escalation only)
A DLT is any toxicity occuring from the first dose of AZD0305 up to and including the planned end of Cycle 1 (the DLT assessment period) that is assessed as unrelated to the disease or disease-related processes under investigation and which includes, any death not clearly due to the underlying disease or extraneous causes, pre-defined haematological and non-haematological toxicities
Time frame: From first dose of AZD0305 until the end of Cycle 1. Cycle 1 (the DLT assessment period is 21 days for Module 1 Group A and 28 days for Module 1 Group B, Module 2, and Module 3)
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Number of patients with adverse events and serious adverse events by system organ class and preferred term
Time frame: From time of Informed consent to 30 days post end of treatment
Frequency of dose modifications, dose delays, and treatment discontinuations due to AEs (Module 2 and Module 3)
Number and percentage of participants with dose modifications, dose delays, and permanent discontinuations due to adverse events (for AZD0305 and combination agent\[s\], as applicable), per protocol-defined dose modification rules.
Time frame: From first dose of study treatment until End of treatment (EOT), assessed up to approximately 2 years (each cycle is 28 days)
Phase Ia: Objective Response Rate (ORR)
The percentage of patients with a confirmed investigator assessed sCR, CR, VGPR or PR according to IMWG criteria
Time frame: From first dose of AZD0305 to progressive disease or Initiation of subsequent MM therapy (approximately 2 years)
Phase Ia: Duration of response (DoR)
The time from the date of first response until date of disease progression or death in the absence of disease progression
Time frame: From the first documented response to confirmed progressive disease or death (approximately 2 years)
Phase Ia: Progression free Survival (PFS)
The time from first dose until IMWG defined disease progression or death
Time frame: From first dose of AZD0305 to progressive disease or death in the absence of disease progression (approximately 2 years)
Phase Ia: Overall Survival (OS)
The time from the date of the first dose of study treatment until death due to any cause
Time frame: From first dose of AZD0305 to death (approximately 2 years)
Phase Ia: Pharmacokinetics of AZD0305: Area Under the concentration-time curve (AUC)
Area under the plasma concentration-time curve
Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of AZD0305 (approximately 2 years)
Phase Ia: Pharmacokinetics of AZD0305: Maximum plasma concentration of the study drug (Cmax)
Maximum observed plasma concentration of the study drug
Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of AZD0305 (approximately 2 years)
Phase Ia: Pharmacokinetics of AZD0305: Time to maximum plasma concentration of the study drug (tmax)
Time to maximum observed plasma concentration of the study drug
Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of AZD0305 (approximately 2 years)
Phase Ia: Pharmacokinetics of AZD0305: Clearance
A pharmacokinetic measurement of the volume of plasma from which the study drug is completely removed per unit time
Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of AZD0305 (approximately 2 years)
Phase Ia: Pharmacokinetics of AZD0305: Terminal elimination half-life (t 1/2)
Terminal elimination half-life
Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of AZD0305 (approximately 2 years)
Phase Ia: Immunogenicity of AZD0305
The number and percentage of participants who develop ADAs
Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of AZD0305 (approximately 2 years)
Phase Ia: Immunogenicity of elranatamab
The number and percentage of participants who develop ADAs
Time frame: From the first dose, at predefined intervals until Cycle 24 administration of elranatamab(approximately 2 years)
Phase Ia: MRD negative CR rate
The percentage of patients who achieve a complete response (CR) and have minimal residual disease (MRD) negativity in bone marrow.
Time frame: From first dose of AZD0305 to progressive disease or death in the absence of disease progression (approximately 2 years)
Phase Ib: Objective Response Rate (ORR)
The percentage of patients with a confirmed investigator assessed sCR, CR, VGPR or PR according to IMWG criteria
Time frame: From randomization/cohort assignment to progressive disease or Initiation of subsequent MM therapy (approximately 2 years)
Phase Ib: Duration of response (DoR)
The time from date of first response until date of disease progression or death in the absence of disease progression
Time frame: From randomization/cohort assignment to confirmed progressive disease or death (approximately 2 years)
Phase Ib: Progression free Survival (PFS)
The time from randomization until IMWG defined disease progression or death
Time frame: From randomization/cohort assignment to progressive disease or death in the absence of disease progression (approximately 2 years)
Phase Ib: Overall Survival (OS)
The time from randomization until death due to any cause
Time frame: From randomization/cohort assignment to death (approximately 2 years)
Phase Ib: Pharmacokinetics of AZD0305: Area Under the concentration-time curve (AUC)
Area under the plasma concentration-time curve
Time frame: From randomization/cohort assignment , at predefined intervals throughout the administration of AZD0305 (approximately 2 years)
Phase Ib: Pharmacokinetics of AZD0305: Maximum plasma concentration of the study drug (Cmax)
Maximum observed plasma concentration of the study drug
Time frame: From randomization/cohort assignment , at predefined intervals throughout the administration of AZD0305 (approximately 2 years)
Phase Ib: Pharmacokinetics of AZD0305: Time to maximum plasma concentration of the study drug (tmax)
Time to maximum observed plasma concentration of the study drug
Time frame: From randomization/cohort assignment , at predefined intervals throughout the administration of AZD0305 (approximately 2 years)
Phase Ib: Pharmacokinetics of AZD0305: Clearance
A pharmacokinetic measurement of the volume of plasma from which the study drug is completely removed per unit time
Time frame: From randomization/cohort assignment , at predefined intervals throughout the administration of AZD0305 (approximately 2 years
Phase Ib: Pharmacokinetics of AZD0305: Terminal elimination half-life (t 1/2)
Terminal elimination half-life
Time frame: From randomization/cohort assignment, at predefined intervals throughout the administration of AZD0305 (approximately 2 years)
Phase Ib: Immunogenicity of AZD0305
The number and percentage of participants who develop ADAs
Time frame: From randomization/cohort assignment, at predefined intervals throughout the administration of AZD0305 (approximately 2 years)
Phase Ib: Immunogenicity of elranatamab
The number and percentage of participants who develop ADAs
Time frame: From the first dose, at predefined intervals until Cycle 24 administration of elranatamab(approximately 2 years)
Phase 1b: MRD negative CR rate (Module 2 and Module 3)
The percentage of patients who achieve a complete response (CR) and have minimal residual disease (MRD) negativity in bone marrow.
Time frame: From first dose of AZD0305 to progressive disease or death in the absence of disease progression (approximately 2 years)
Complete Response Rate (CRR) - Mod2&3 only
Percentage of participants achieving a confirmed CR or sCR per IMWG criteria.
Time frame: From first dose of combination treatment to progressive disease or initiation of subsequent multiple myeloma therapy (approximately 2 years)
Pre-Dose Plasma Concentration of Elranatamab (pharmacokinetics - Module 2 only)
Pre-dose Plasma concentrations for elranatamab.
Time frame: From the first dose of study intervention, at predefined intervals until Cycle 24 administration of elranatamab(approximately 2 years; 1 cycle = 28 days)
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
No publications or documents are linked to this record.
Started Dec 2023 (actual). Primary completion is estimated for Jan 2028, 49 months after the start.
Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's planned 49 months is below that.
Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Aug 2027 → Jan 2028 and completion Aug 2027 → Jan 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.